VANCOUVER, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous…


Previous articleNuminus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
Next articlePT390 – Vital Psychedelic Conversations